TS
BCRX icon

Thomas Steyer’s BioCryst Pharmaceuticals BCRX Stock Holding History

Thomas Steyer’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,000
Closed -$228K – 101
2026
Q1 		$228K Hold
24,000
– – ﹤0.01% 136
2025
Q4 		$187K Hold
24,000
– – ﹤0.01% 138
2025
Q3 		$182K Buy
+24,000
New +$200K ﹤0.01% 126

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Thomas Steyer's BCRX Position: Q2 2026 in Review

Thomas Steyer sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 24,000 shares — an estimated $228K sold.

Thomas Steyer first reported a position in BCRX in Q3 2025 and held it in 3 quarters. The position peaked at $228K in Q1 2026. 316 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Thomas Steyer reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Thomas Steyer sold 24,000 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $228K.
  • Thomas Steyer first reported a position in BioCryst Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Thomas Steyer's BioCryst Pharmaceuticals position peaked at $228K in Q1 2026.
  • 316 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.